Proact Q1 review: Slightly reduced ebita and base case - Redeye
Redeye retains its neutral view on Proact following a soft Q1 due to a weak BU West. Management believes the weakness is Corona-related, implying a high likelihood for improvements in H2. We lower our forecasts and Base case slightly.
ANNONS
Redeye retains its neutral view on Proact following a soft Q1 due to a weak BU West. Management believes the weakness is Corona-related, implying a high likelihood for improvements in H2. We lower our forecasts and Base case slightly.